These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 17301739)

  • 1. Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer.
    Hunz M; Jetter A; Warm M; Pantke E; Tuscher M; Hempel G; Jaehde U; Untch M; Kurbacher C; Fuhr U
    Clin Pharmacol Ther; 2007 May; 81(5):659-68. PubMed ID: 17301739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
    Tanei T; Morimoto K; Shimazu K; Kim SJ; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
    Clin Cancer Res; 2009 Jun; 15(12):4234-41. PubMed ID: 19509181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and myocardial enzyme profiles of two administration routes of epirubicin in breast cancer patients.
    Yang RX; Ren HX; Zhuang L; Gao CL; Dong C; Luo CX; Wang XN; Feng EF; He JC
    Arzneimittelforschung; 2012 Dec; 62(12):677-81. PubMed ID: 23203544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel plus epirubicin in advanced breast cancer.
    Conte PF; Gennari A; Salvadori B; Pazzagli C; Bengala C
    Oncology (Williston Park); 1998 Jan; 12(1 Suppl 1):40-4. PubMed ID: 9516603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A population model of epirubicin pharmacokinetics and application to dosage guidelines.
    Ralph LD; Thomson AH; Dobbs NA; Twelves C
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):34-40. PubMed ID: 12764671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations.
    D'Incalci M; Schüller J; Colombo T; Zucchetti M; Riva A
    Semin Oncol; 1998 Dec; 25(6 Suppl 13):16-20. PubMed ID: 9865687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epirubicin as adjuvant therapy in breast cancer.
    Earl H; Iddawela M
    Expert Rev Anticancer Ther; 2004 Apr; 4(2):189-95. PubMed ID: 15056049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patients.
    Müller M; Mader RM; Steiner B; Steger GG; Jansen B; Gnant M; Helbich T; Jakesz R; Eichler HG; Blochl-Daum B
    Cancer Res; 1997 Jul; 57(13):2598-601. PubMed ID: 9205062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763.
    Miller AA; Rosner GL; Egorin MJ; Hollis D; Lichtman SM; Ratain MJ
    Clin Cancer Res; 2004 Dec; 10(24):8325-31. PubMed ID: 15623609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer response to paclitaxel in vivo.
    Symmans FW
    Drug Resist Updat; 2001 Oct; 4(5):297-302. PubMed ID: 11991683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study.
    Pires LA; Hegg R; Valduga CJ; Graziani SR; Rodrigues DG; Maranhão RC
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):281-7. PubMed ID: 18365196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epirubicin for breast cancer during pregnancy: a case report.
    Eedarapalli P; Biswas N; Coleman M
    J Reprod Med; 2007 Aug; 52(8):730-2. PubMed ID: 17879836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of tumor biological factors on response to pre-operative epirubicin and paclitaxel chemotherapy in primary breast cancer.
    Warm M; Kates R; Mallmann P; Dick M; Nawroth F; Harbeck N; Paepke S; Thomas A
    Anticancer Res; 2007; 27(2):1031-8. PubMed ID: 17465239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers.
    Dias ML; Carvalho JP; Rodrigues DG; Graziani SR; Maranhão RC
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):105-11. PubMed ID: 16699792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment.
    Symmans WF; Volm MD; Shapiro RL; Perkins AB; Kim AY; Demaria S; Yee HT; McMullen H; Oratz R; Klein P; Formenti SC; Muggia F
    Clin Cancer Res; 2000 Dec; 6(12):4610-7. PubMed ID: 11156210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity.
    Prado CM; Lima IS; Baracos VE; Bies RR; McCargar LJ; Reiman T; Mackey JR; Kuzma M; Damaraju VL; Sawyer MB
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):93-101. PubMed ID: 20204364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonlinear pharmacokinetics of paclitaxel in ovarian cancer patients.
    Ye M; Zhu Z; Fu Q; Shen K; Li DK
    Acta Pharmacol Sin; 2000 Jul; 21(7):596-9. PubMed ID: 11360664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients.
    Esposito M; Venturini M; Vannozzi MO; Tolino G; Lunardi G; Garrone O; Angiolini C; Viale M; Bergaglio M; Del Mastro L; Rosso R
    J Clin Oncol; 1999 Apr; 17(4):1132. PubMed ID: 10561171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer.
    Untch M; Möbus V; Kuhn W; Muck BR; Thomssen C; Bauerfeind I; Harbeck N; Werner C; Lebeau A; Schneeweiss A; Kahlert S; von Koch F; Petry KU; Wallwiener D; Kreienberg R; Albert US; Lück HJ; Hinke A; Jänicke F; Konecny GE
    J Clin Oncol; 2009 Jun; 27(18):2938-45. PubMed ID: 19364964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.